Previous 10 | Next 10 |
2023-10-05 06:24:08 ET Summary PepGen is a small-cap healthcare company focused on developing therapies for genetic disorders, particularly Duchenne muscular dystrophy. The company's Enhanced Delivery Oligonucleotide platform shows promising results in increasing the delivery and ...
BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that it will be p...
BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced it has recei...
- EDO platform observed to drive 25-fold higher level of oligonucleotide delivery to myotube nuclei compared to “naked” oligonucleotide - - EDO technology enabled delivery of therapeutic oligonucleotide to 72% of muscle nuclei in non-human primates - - PGN-EDODM1 c...
BOSTON, Sept. 01, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that it will be p...
2023-08-08 10:48:40 ET PepGen press release ( NASDAQ: PEPG ): Q2 GAAP EPS of -$0.82. Cash and cash equivalents were $147.0 million as of June 30, 2023, which is anticipated to fund currently planned operations into early 2025. Research and Development expenses were $16...
– Phase 2 open-label CONNECT1-EDO51 study open in Canada – – Potentially registrational, randomized, double-blind, placebo-controlled Phase 2 CONNECT2-EDO51 multinational study expected to be initiated in the second half of 2023 – – Continue to...
2023-06-20 04:53:07 ET Summary PepGen Inc. recently faced a setback with the FDA's clinical hold notice on its PGN-EDODM1 compound. Despite this, the company has received approval to proceed with the CONNECT1-EDO51 study in Canada. With mixed prospects in the medium-term, reit...
2023-06-13 16:59:12 ET PepGen is withdrawing guidance that anticipated starting a phase 1 study of PGN-EDODM1 in myotonic dystrophy type 1 (DM1) in H1. The reason for the delay is to address issues with an FDA clinical hold on a investigational New Drug ( IND ) applicatio...
BOSTON, June 13, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that while it...
News, Short Squeeze, Breakout and More Instantly...
2024-07-06 15:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the expansion of its executive team with the appointments of...
Michelle Mellion, M.D., promoted to Chief Medical Officer Hayley Parker, Ph.D., promoted to Senior Vice President, Global Regulatory Affairs PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of t...